Humana: Solid Medicare Moat, But Upside Stalls Near Fair Value
By stockpickr AI | March 2, 2026 | 10 min read
Investment Summary
Humana (Healthcare) appears slightly undervalued based on the DCF valuation, showcasing a stable business model anchored in the growing Medicare Advantage sector.
Investment Recommendation
Hold
Fair Value: $378.50
Current Price: $361.62
Upside/Downside: +4.67%
The DCF analysis yields an implied fair value slightly above the current market price. Given the regulatory overhangs specific to the insurance industry, maintaining a price-neutral stance is warranted, aligning with the company's current valuation stability.
Key Metrics
- Market Cap: $38.86B
- P/E Ratio: 17.46x
- Forward P/E: 14.98x
- Revenue Growth (YoY): 11.1%
- Net Margin: 2.9%
- ROE: 14.5%
- Debt/Equity: 0.58
- Dividend Yield: 1.42%
Strengths
- Strong market share in the high-growth Medicare Advantage segment, exceeding 10 million members.
- Revenue grew 11.1% year-over-year in the most recent period, demonstrating solid top-line momentum.
- Efficient cash generation, evidenced by a trailing twelve-month free cash flow of approximately $5,891 million.
- Relatively low beta (0.74), suggesting lower volatility compared to the broader market.
Risk Factors
- Regulatory uncertainty regarding Medicare Advantage reimbursement rates and risk adjustment factors remains a primary headwind.
- Medical cost inflation is pressuring M&A ratios, as seen by a recent slight dip in reported margins.
- Increased competition from new entrants and existing national health plans intensifying market share battles.